At the news
? NEUTRALIMPACT 3/10 144 filed Mar 31, 2026 at 21:57 ET
OrbiMed Advisors LLC, on behalf of its affiliate OrbiMed Genesis Master Fund, LP, has filed a Form 144 to notify intent to sell up to 45,057 shares of Keros Therapeutics (KROS) common stock. The shares were acquired in connection with KROS's IPO on April 13, 2020, and are now eligible for sale under Rule 144.
- Reporting entity: OrbiMed Advisors LLC, acting for OrbiMed Genesis Master Fund, LP
- Number of shares proposed for sale: 45,057
- Shares acquired: April 13, 2020 (IPO date)
- Filing date: March 31, 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access